The Role of Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Seminars in Radiation Oncology

Volumn 22, Issue 3, 2012, Pages 198-206

  Nwizu, Tobenna ^a   Ghi, Maria Grazia ^b   Cohen, Ezra E W ^a   Paccagnella, Adriano ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Department of Medical Oncology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; PANITUMUMAB; PLATINUM DERIVATIVE; VINCRISTINE;

ADVANCED CANCER; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; CHEMORADIOTHERAPY; DERMATITIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; DRUG BINDING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FEASIBILITY STUDY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; LARYNGECTOMY; LARYNX; META ANALYSIS; MONOTHERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SKIN TOXICITY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 84862149186     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.03.004     Document Type: Review

References (69)

1. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000, 355:949-955.
2. Pignon J.P., le Maître A., Maillard E., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
3. Steel G.G., Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 1979, 5:85-91.
4. Hennequin C., Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer 2002, 38:223-230.
5. Tannock I.F., Rotin D. Mechanisms of interaction between radiation and drugs with potential for improvements in therapy. NCI Monogr 1988, 6:77-83.
6. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350:1937-1944.
7. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004, 350:1945-1952.
8. Bernier J., Cooper J.S. Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence?. Oncologist 2005, 10:215-224.
9. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005, 27:843-850.
10. Blanchard P., Baujat B., Holostenco V., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol 2011, 100:33-40.
11. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-2098.
12. Forastiere A.A., Weber R.S. Long-term results of intergroup RTOG 91-11: A phase III trial to preserve the larynx-induction cisplatin/5FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 2006, 24(suppl 18):284. Abstract 5517.
13. Munro A.J. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995, 71:83-91.
14. Grégoire V., Lefebvre J.L., Licitra L., et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v184-v186.
15. Ang K., Zhang Q., Wheeler R.H. A phase III trial (ROTG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome. J Clin Oncol 28(suppl 7) 2010, Abstract 5507.
16. Bourhis J., Lapeyre M., Tortochaux J., et al. Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: Results of a GORTEC randomized trial. Radiother Oncol 2011, 100:56-61.
17. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 2006, 368:843-854.
18. Trotti A., Bellm L.A., Epstein J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 2003, 66:253-262.
19. Eriksen J.G., Steiniche T., Overgaard J., et al. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 2005, 74:93-100.
20. Van den Bogaert W., Van der Leest A., Rijnders A., et al. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer?. Radiother Oncol 1995, 36:177-182.
21. Nutting C.M., Morden J.P., Harrington K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12:127-136.
22. Machtay M., Moughan J., Trotti A., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 2008, 26:3582-3589.
23. Argiris A., Brockstein B.E., Haraf D.J., et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004, 10:1956-1962.
24. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20(suppl 18):1S-13S.
25. Hitt R., Ciruelos E., Amador M.L., et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005, 41:453-460.
26. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000, 6:2166-2174.
27. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
28. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28.
29. Pryor D.I., Porceddu S.V., Burmeister B.H., et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 2009, 90:172-176.
30. Lefebvre J.L., Pointreau Y., Rolland F. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol 29(suppl 15) 2011, Abstract 5501.
31. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006, 24:1072-1078.
32. Merlano M., Russi E., Benasso M., et al. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: A phase II clinical study. Ann Oncol 2011, 22:712-717.
33. Ang K.K., Zhang Q., Rosenthal D.I. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinoma. J Clin Oncol 2011, 29. Abstract 5500.
34. Ghi M.G., Floriani I. Concomitant chemoradiation in locally advanced head and neck squamous cell chemotherapy. carcinoma: A literature based meta-analysis on the platinum concomitant J Clin Oncol 2011, 29. Abstract 5534.
35. Sturgis E.M., Ang K.K. The epidemic of HPV-associated oropharyngeal cancer is here: Is it time to change our treatment paradigms?. J Natl Compr Canc Netw 2011, 9:665-673.
36. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720.
37. Nguyen N.P., Chi A., Nguyen L.M., et al. Human papillomavirus-associated oropharyngeal cancer: A new clinical entity. QJM 2010, 103:229-236.
38. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991, 324:1685-1690.
39. Lefebvre J.L., Chevalier D., Luboinski B., et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC head and neck cancer Cooperative Group. J Natl Cancer Inst 1996, 88:890-899.
40. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994, 86:265-272.
41. Zorat P.L., Paccagnella A., Cavaniglia G., et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004, 96:1714-1717.
42. Domenge C., Hill C., Lefebvre J.L., et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer 2000, 83:1594-1598.
43. Rooney M., Kish J., Jacobs J., et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985, 55:1123-1128.
44. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357:1695-1704.
45. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357:1705-1715.
46. Lorch J.H., Goloubeva O., Haddad R.I., et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011, 12:153-159.
47. Pointreau Y., Garaud P., Chapet S., et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009, 101:498-506.
48. Ready N.E., Rathore R., Johnson T.T., et al. Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 2011, 35:6-12.
49. Argiris A., Heron D.E., Smith R.P., et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010, 28:5294-5300.
50. Kies M.S., Holsinger F.C., Lee J.J., et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial. J Clin Oncol 2010, 28:8-14.
51. Cohen E, Karrison T, Kochergminsky M, et al: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol suppl; abstr 5500.
52. Haddad RI, Rabinowitz G, Tishler RB, et al: The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). J Clin Oncol Suppl; abstr 5501.
53. Salvajoli J.V., Morioka H., Trippe N., et al. A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 1992, 249:211-215.
54. Quon H., Leong T., Haselow R., et al. Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382). Int J Radiat Oncol Biol Phys 2011, 81:719-725.
55. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998, 338:1798-1804.
56. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998, 16:1318-1324.
57. Weissler M.C., Melin S., Sailer S.L., et al. Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1992, 118:806-810.
58. Huguenin P., Beer K.T., Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004, 22:4665-4673.
59. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000, 18:1458-1464.
60. Jeremic B., Shibamoto Y., Stanisavljevic B., et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997, 43:29-37.
61. Fountzilas G., Ciuleanu E., Dafni U., et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol 2004, 21:95-107.
62. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21:92-98.
63. Bensadoun R.J., Benezery K., Dassonville O., et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006, 64:983-994.
64. Adelstein D.J., Lavertu P., Saxton J.P., et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000, 88:876-883.
65. Sharma A., Mohanti B.K., Thakar A., et al. Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial. Ann Oncol 2010, 21:2272-2277.
66. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999, 91:2081-2086.
67. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001, 50:1161-1171.
68. Olmi P., Crispino S., Fallai C., et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy-a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003, 55:78-92.
69. Ruo Redda M.G., Ragona R., Ricardi U., et al. Radiotherapy alone or with concomitant daily low-dose carboplatin in locally advanced, unresectable head and neck cancer: definitive results of a phase III study with a follow-up period of up to ten years. Tumori 2010, 96:246-253.